Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone925-288-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.91 million
Profitability
Miscellaneous
Employees240
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $18.20 million for the quarter, compared to analyst estimates of $17.55 million. Cerus had a negative return on equity of 85.73% and a negative net margin of 98.69%. The firm's revenue for the quarter was up 18.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) EPS. View Cerus' Earnings History.
When is Cerus' next earnings date?
What guidance has Cerus issued on next quarter's earnings?
Cerus issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $72-75 million, compared to the consensus revenue estimate of $93.48 million.
What price target have analysts set for CERS?
3 analysts have issued 1-year price targets for Cerus' shares. Their forecasts range from $7.00 to $9.00. On average, they expect Cerus' share price to reach $8.00 in the next year. This suggests a possible upside of 50.1% from the stock's current price. View Analyst Price Targets for Cerus.
What is the consensus analysts' recommendation for Cerus?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.
Has Cerus been receiving favorable news coverage?
News articles about CERS stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cerus earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Cerus.
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Silk Road Medical (SILK), Cryolife (CRY), AtriCure (ATRC), Luminex (LMNX), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX) and Anika Therapeutics (ANIK).
What other stocks do shareholders of Cerus own?
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 52)
- Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
- Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
- Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)
Who are Cerus' major shareholders?
Cerus' stock is owned by many different of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (8.05%), BlackRock Inc. (7.83%), ARK Investment Management LLC (6.16%), Vanguard Group Inc. (4.99%), Nikko Asset Management Americas Inc. (3.66%) and Sumitomo Mitsui Trust Holdings Inc. (3.66%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.
Which institutional investors are selling Cerus stock?
CERS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, King Luther Capital Management Corp, AQR Capital Management LLC, A.R.T. Advisors LLC, Bank of Montreal Can, BNP Paribas Arbitrage SA and Wells Fargo & Company MN. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.
Which institutional investors are buying Cerus stock?
CERS stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., D. E. Shaw & Co. Inc., ARK Investment Management LLC, First Midwest Bank Trust Division, Nuveen Asset Management LLC, Bank of America Corp DE and Primecap Management Co. CA. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash and William Mariner Greenman. View Insider Buying and Selling for Cerus.
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $5.33.
How big of a company is Cerus?
Cerus has a market capitalization of $747.91 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.
What is Cerus' official website?
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (NASDAQ CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
